Visualize the future of precision medicine with Bio-Techne’s multiomics platform: CRC case study
Bio-Techne’s multiomics platform provides a comprehensive view of disease by combining genomic data with data from other modalities, including transcriptomics, epigenomics, and proteomics. This approach enables a multifaceted understanding of the molecular changes contributing to disease, allowing researchers to connect genotypes to phenotypes and discover novel drug targets and biomarkers.
A pilot study in colorectal cancer (CRC) screening using the Bio-Techne platform shows the value of integrating multiomic readouts for enhanced CRC classification. The underlying platform can be applied to biomarker signature development and is designed for extension to downstream assay development for clinical trial applications.
Key takeaways:
- Bio-Techne is developing a liquid biopsy platform that analyzes gene expression, splice variants, gene fusions, mutations, DNA methylation, and proteins. This platform integrates bioinformatics and machine learning for discovery of multi-analyte biomarker signatures, allowing a multifaceted view of a patient’s disease.
- ExosomeDx, a Bio-Techne brand’s, proprietary exosome technologies are designed to enable the detection of early disease indicators with improved sensitivity, aiming to provide early diagnosis. We have developed the first exosome-based liquid biopsy clinical test on the market (LDT), the ExoDx Prostate Test.
This content was provided by
